However, the extent as well as targets of glioma hypermethylation seem to vary considerably when compared to that observed in other IDHmut cancers such as acute myeloid leukemia (AML), possibly explaining why IDH mutational status serves as a favorable prognostic biomarker in GBM only (10). This evidence concerns the gene IDH1 and acute myeloid leukemia.